GLP-1 Medications Are Getting More Affordable Than Ever in 2026

If there's one thing that defined 2025, it was the frustration of wanting GLP-1 medication but facing a $1,000+ monthly price tag. In 2026, that story has fundamentally changed — and the changes are all in patients' favor.

The Price Landscape Has Transformed

In just 18 months, the cost of GLP-1 treatment has collapsed. What used to cost $1,349/month for brand-name Wegovy can now be accessed for as little as $50/month through Medicare, $99/month through telehealth compounding providers, or $245/month through the TrumpRx negotiated pricing program. This isn't a temporary sale — it's a structural shift driven by competition, policy, and new oral formulations that are cheaper to manufacture.

What Changed — and Why It's Great News

Medicare coverage is finally here

Starting July 1, 2026, the Medicare GLP-1 Bridge program offers Wegovy (injectable and pill), Zepbound, and Foundayo for a $50 monthly copay. This is a historic milestone — Medicare has been prohibited from covering weight loss drugs since 2003. For the first time, seniors with obesity can access proven treatment at an affordable price.

Oral GLP-1 pills changed the manufacturing equation

Foundayo (orforglipron), approved April 2026, is a small-molecule pill — dramatically cheaper to produce than injectable peptides. Ozempic tablets launched May 2026 at $149/month self-pay. More oral options (elecoglipron from AstraZeneca) are in the pipeline. Competition between oral manufacturers will continue pushing prices down.

TrumpRx negotiated landmark pricing

The negotiated agreements with Novo Nordisk and Eli Lilly brought brand-name GLP-1 pricing to $245/month — less than one-fifth of previous retail prices. This applies to Ozempic, Wegovy, Mounjaro, and Zepbound through the TrumpRx program.

Compounding providers compete on value

Compounding pharmacies have pushed prices as low as $99/month for semaglutide, with providers like GobyMeds and YourEra Health offering all-inclusive pricing that doesn't increase with dose escalation. While compounding faces regulatory uncertainty, it remains a viable option in 2026.

How to Find the Cheapest Option for You

If you're on Medicare: Ask your doctor about the Medicare GLP-1 Bridge starting July 1. At $50/month, it's the most affordable FDA-approved option available.

If you have commercial insurance: Check whether your plan covers GLP-1 medications. Many now do, with copays as low as $25/month when combined with manufacturer savings cards.

If you're paying cash: Oral semaglutide at $149/month through NovoCare, or compounded semaglutide from $99/month through providers like GobyMeds, offer excellent value.

If you want brand-name without insurance: TrumpRx pricing at $245/month for Wegovy or Zepbound is the best cash-pay option for FDA-approved medication.